Equity Investment Corp Grows Stock Holdings in Medtronic PLC $MDT

Equity Investment Corp lifted its stake in Medtronic PLC (NYSE:MDT) by 1.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,519,679 shares of the medical technology company’s stock after buying an additional 21,696 shares during the period. Medtronic comprises approximately 3.0% of Equity Investment Corp’s holdings, making the stock its 5th largest holding. Equity Investment Corp owned approximately 0.12% of Medtronic worth $144,734,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Riverbend Wealth Management LLC lifted its holdings in shares of Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after acquiring an additional 107 shares during the period. Wynn Capital LLC increased its position in shares of Medtronic by 2.4% during the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after purchasing an additional 110 shares in the last quarter. Meridian Investment Counsel Inc. lifted its holdings in Medtronic by 0.4% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock valued at $2,692,000 after purchasing an additional 110 shares during the last quarter. Saxony Capital Management LLC lifted its holdings in Medtronic by 3.8% during the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 112 shares during the last quarter. Finally, Cape Investment Advisory Inc. boosted its position in Medtronic by 3.2% in the second quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after buying an additional 113 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Medtronic stock opened at $103.21 on Wednesday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company’s 50-day moving average is $99.55 and its two-hundred day moving average is $95.92. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a market cap of $132.31 billion, a PE ratio of 27.82, a PEG ratio of 2.71 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wells Fargo & Company initiated coverage on shares of Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Truist Financial dropped their price target on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Citigroup started coverage on Medtronic in a research note on Tuesday. They issued a “buy” rating and a $117.00 price objective on the stock. UBS Group increased their target price on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Finally, William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $110.56.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic will acquire CathWorks for up to $585 million, adding the CathWorks FFRangio® diagnostic system and broader AI-enabled heart-imaging capabilities to its cath-lab portfolio — a strategic bolt-on to accelerate growth in interventional cardiology and digital heart care. Medical device maker Medtronic to buy CathWorks in up to $585 million deal
• Positive Sentiment: Medtronic highlights the acquisition as advancing its innovation strategy and follows an existing 2022 strategic partnership/co-promotion — signaling faster commercialization and lower early-stage integration risk than a greenfield deal. Medtronic advances its innovation strategy with intent to acquire CathWorks
• Positive Sentiment: Medtronic Diabetes secured Medicare access and new FDA clearances for the MiniMed 780G system (including use with ultra‑rapid‑acting insulins and for insulin‑requiring type 2 diabetes), expanding addressable market and reimbursement coverage. Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances
• Positive Sentiment: New analyst coverage is bullish: Citigroup initiated coverage with a Buy and $117 price target (~13% upside from current levels), which can attract buyers and support multiple expansion. (Coverage note from brokerage reports)
• Neutral Sentiment: Wells Fargo also started research coverage on MDT, broadening institutional attention but not yet translating into a consensus rating change. Medtronic (NYSE:MDT) Research Coverage Started at Wells Fargo & Company
• Neutral Sentiment: Industry commentary notes that Wall Street remains moderately optimistic on MDT despite recent underperformance versus the S&P 500 — sentiment supportive but not catalytic. Are Wall Street Analysts Predicting Medtronic Stock Will Climb or Sink?
• Negative Sentiment: Deal risks: the acquisition is subject to U.S. regulatory approval and integration/execution risk; investors should watch regulatory milestones and any contingent payments up to $585M that could affect near-term cash flow. Medtronic Bets On AI Heart Care With $585 Million Deal For Partner CathWorks

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).